Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Binex and MaxCyte collaborate for cancer research
Upon completion of the research studies, the agreement provides Binex an option to license MaxCyte’s technology for clinical and commercial use in Korea. Baek Chun Lee, Binex’s chairman,
Upon completion of the research studies, the agreement provides Binex an option to license MaxCyte’s technology for clinical and commercial use in Korea. Baek Chun Lee, Binex’s chairman,
This tentative approval is for the generic bioequivalent product to Lexapro, which is offered by Forest Laboratories. Daniel Movens, CEO of Caraco Pharmaceutical Laboratories, said: “We are extremely
Under the terms of the agreement, ChemDiv will deploy the Discovery outSource platform for Orion’s discovery program, including chemical library, proprietary rational design, assay development and bioscreening. ChemDiv
The pre-specified interim Phase III (Prepare study) results relate to the study period when chemotherapy and Aranesp were administered, and specifically address the tumor response to chemotherapy at
Alcon says the active ingredient in Triesence, triamcinolone acetonide, has been used for many years to treat retinal disease. The company said that this new approval brings ophthalmologists
The conditions outlined in the panel’s recommendations related to clarifications on labeling for the device regarding small patients and those unable to be treated with anti-coagulation therapy, and
Vaccinex said that it is using its patented technology to discover and develop new monoclonal antibody therapies, and has advanced four of its lead therapeutic antibodies into preclinical
Under the terms of the agreement, Prometheus made an up-front payment which may be followed by additional payments on the successful achievement of future development milestones, including FDA
Under the agreement, signed in June 2006 and extended to cover additional work in December 2006, Arana utilized its superhumanization technology to develop humanized versions of lead antibodies
The application includes three lacosamide formulations, tablets, syrup and an intravenous injection. The proposed trade name for lacosamide is Vimpat. The new drug application (NDA) for lacosamide in